United States Patent 4,663,318: Galanthamine Alzheimer’s Treatment Claims and Patent Landscape

United States Patent No. 4,663,318 claimed the use of galanthamine, including pharmaceutically acceptable acid-addition salts, to treat Alzheimer’s disease and related dementias. The patent issued May 5, 1987, and expired May 5, 2004, under the pre-Uruguay Round patent term of 17 years from issuance. It no longer creates an enforceable barrier to galanthamine products, generic entry, or approved Alzheimer’s disease uses.

The patent’s commercial importance was historical. It covered the therapeutic concept later associated with galantamine hydrobromide products such as Razadyne and Reminyl, but it did not protect the galanthamine molecule itself, a particular tablet or capsule formulation, a manufacturing process, or the modern FDA-approved dose range.

What does United States Patent 4,663,318 cover?

US 4,663,318 covers a method of treating Alzheimer’s disease and related dementias by administering a therapeutically effective amount of galanthamine or a pharmaceutically acceptable acid-addition salt.

Patent element	Scope
Active ingredient	Galanthamine, including pharmaceutically acceptable acid-addition salts
Primary disease	Alzheimer’s disease
Additional disease scope	“Related dementias”
Claim type	Method-of-treatment claims
Composition claims	None in the listed claims
Formulation claims	None in the listed claims
Manufacturing claims	None in the listed claims
Route claims	Oral, parenteral, and intracerebroventricular administration
Status	Expired
Issue date	May 5, 1987
Expiration date	May 5, 2004
Patent owner listed in historical records	Janssen Pharmaceutica N.V.

The patent is therefore a use patent. A product containing galanthamine would not infringe the patent merely because it contains galanthamine. Infringement would have required conduct within the method claims, such as administering galanthamine for the claimed disease during the enforceable term.

How do the six dependent claims narrow the patent scope?

Claims 2 through 7 narrow claim 1 by adding administration routes and dose ranges. They do not create separate composition or product claims.

Claim 1: broad Alzheimer’s disease treatment method

Claim 1 requires:

A patient suffering from Alzheimer’s disease or a related dementia;
Administration of galanthamine or a pharmaceutically acceptable acid-addition salt; and
A therapeutically effective amount.

The claim does not specify:

A particular salt, such as galanthamine hydrobromide;
A tablet, capsule, oral solution, injection, or implant;
A release profile;
A dosing frequency;
A treatment duration;
A patient subgroup;
A biomarker;
A combination therapy; or
A particular mechanism of action.

Its breadth came from the absence of product and formulation limitations. A court assessing infringement would have focused on whether the accused conduct involved administering galanthamine to treat Alzheimer’s disease or a related dementia.

The phrase “related dementias” expands the claim beyond Alzheimer’s disease, but it also creates a claim-construction issue. The term would likely be interpreted in light of the specification and the knowledge available at the filing date. It would not automatically cover every cognitive disorder or every disease involving memory loss.

Claims 2 and 3: parenteral dosing

Claim 2 requires parenteral administration at 5 to 1,000 mg per day. Claim 3 narrows that range to 50 to 300 mg per day.

“Parenteral” ordinarily includes administration by injection or another route that bypasses the gastrointestinal tract. The claims do not specify intravenous, intramuscular, subcutaneous, or another particular injection route.

The claimed doses are substantially higher than the current FDA-approved oral galantamine doses. The claims should therefore be read as historical patent limitations, not as a description of present clinical practice.

Claims 4 and 5: oral dosing

Claim 4 requires oral administration at 10 to 2,000 mg per day. Claim 5 narrows the range to 100 to 600 mg per day.

These claims potentially reach tablets, capsules, oral solutions, and other orally administered products, provided the product is used within the claimed disease and dose limitations. They do not require immediate release or extended release.

The ranges are broad. Claim 4 includes doses below and above the approved range, while claim 5 is far above the approved daily dose used for marketed galantamine products.

Claim 6: parenteral weight-based dosing

Claim 6 requires parenteral administration at 0.1 to 4 mg/kg of patient body weight.

This claim differs from claims 2 and 3 because it uses a weight-based dose rather than a fixed daily amount. It is dependent on claim 1, not on claim 2. The claim therefore does not expressly require the fixed 5 to 1,000 mg daily range in claim 2.

Claim 7: intracerebroventricular administration

Claim 7 requires administration into the brain’s ventricular system through an implanted reservoir at 0.01 to 5.0 mg/kg per day.

This is the narrowest and most technically specific claim. It requires:

Intracerebroventricular delivery;
An implanted reservoir;
A weight-based daily dose; and
Treatment within the scope of claim 1.

The claim does not cover ordinary oral galantamine products. Its practical importance was limited by the invasive nature of the delivery system and the absence of an approved intracerebroventricular galantamine product.

When did US 4,663,318 lose exclusivity?

US 4,663,318 expired on May 5, 2004.

Event	Date
Patent filing and priority period	Mid-1980s
Patent issued	May 5, 1987
Statutory term under pre-1995 law	17 years from issuance
Patent expiration	May 5, 2004
Current enforceability	None
Patent term extension relevance	None identified for this patent
Patent term adjustment relevance	None under the applicable historical term

The patent was issued before the June 8, 1995 change to a 20-year term measured from the earliest effective nonprovisional filing date. Its term was governed by the older 17-year-from-issuance rule.

No current product launch can infringe an expired patent. The patent also cannot support a current Paragraph IV lawsuit, an injunction against a generic, or a royalty demand based solely on the patent claims.

What is the FDA regulatory status of galantamine?

Galantamine is an FDA-approved small-molecule acetylcholinesterase inhibitor for mild to moderate Alzheimer’s dementia. The FDA approved the original product under the brand name Reminyl. The product was later renamed Razadyne because of medication-error concerns involving the name Reminyl and the diabetes product Amaryl.

The marketed FDA dosage forms include:

Immediate-release tablets;
Oral solution; and
Extended-release capsules.

The FDA-approved adult dosing range is materially narrower than the ranges in US 4,663,318. The Razadyne label describes immediate-release dosing generally within a 8 to 24 mg/day maintenance range, with extended-release dosing generally within the same overall daily range. Dose escalation is gradual because of gastrointestinal and other adverse effects.[1]

Product category	Regulatory position
Galantamine immediate-release tablets	FDA-approved generic and branded products
Galantamine oral solution	FDA-approved product category
Galantamine extended-release capsules	FDA-approved branded and generic product category
Galantamine injection	Not the standard FDA-approved commercial dosage form
Intracerebroventricular galantamine reservoir	No established FDA-approved commercial product
Biosimilar pathway	Not applicable
ANDA pathway	Applicable to generic small-molecule products

Galantamine is not a biologic. Biosimilar litigation and the Biologics Price Competition and Innovation Act do not apply. Generic manufacturers use the Abbreviated New Drug Application pathway.

What is the Orange Book status of US 4,663,318?

US 4,663,318 is not a current Orange Book barrier because it expired in 2004.

The Orange Book historically identified patents associated with approved galantamine products, but the relevant commercial protection for Razadyne and its dosage forms extended beyond the original method patent. Later patents could have addressed extended-release delivery, dosage forms, or other product characteristics. Those later rights had to be evaluated separately from US 4,663,318.[2]

The key distinction is:

Protection type	Relationship to US 4,663,318
Alzheimer’s disease method claim	Covered by US 4,663,318
Galantamine molecule	Not created by this patent
Galantamine hydrobromide composition	Not specifically claimed in the listed claims
Immediate-release tablet	Not specifically claimed
Extended-release capsule	Not specifically claimed
Manufacturing process	Not claimed
Current Orange Book blocking patent	Not US 4,663,318

An expired patent may remain historically listed in patent databases, litigation records, or regulatory histories. Historical listing does not restore enforceability.

What formulations are protected by the patent?

The listed claims do not contain a formulation limitation. Claim 1 can theoretically cover the administration of galanthamine in any dosage form, but only as a method of treatment and only during the patent term.

The claims do not require:

A sustained-release matrix;
A specific polymer;
A multiparticulate capsule;
A defined dissolution profile;
A specified particle size;
A particular excipient;
A specific salt-selection process; or
A manufacturing step.

This distinction matters in generic competition. A later formulation patent could have protected an extended-release capsule even after US 4,663,318 expired. A generic manufacturer could then challenge the later formulation patent while relying on the expiration of the original treatment patent.

How does the claimed dose compare with approved galantamine dosing?

The patent’s dose ranges are much broader and, in several claims, much higher than the FDA-approved dosing described in the Razadyne labeling.

Patent claim	Dose and route	Comparison with approved oral dosing
Claim 2	5-1,000 mg/day, parenteral	Not representative of approved oral therapy
Claim 3	50-300 mg/day, parenteral	Well above ordinary approved daily dosing
Claim 4	10-2,000 mg/day, oral	Includes the approved range but extends far beyond it
Claim 5	100-600 mg/day, oral	Above the approved range
Claim 6	0.1-4 mg/kg, parenteral	Weight-based invasive administration
Claim 7	0.01-5 mg/kg/day, intracerebroventricular	Experimental and highly specific delivery route

The approved product labeling, rather than the historical patent, controls clinical dosing and regulatory use. A patent claim can cover a dose range that is not approved, clinically customary, or commercially used. That does not convert the claimed range into an FDA-approved indication.

How strong was the patent estate for galantamine?

US 4,663,318 was commercially meaningful because it linked galantamine to Alzheimer’s disease treatment. Its legal scope was narrower than a compound patent but broader than a formulation patent because claim 1 did not limit the treatment to a specific dosage form or salt.

Its principal strengths were:

Broad therapeutic-use language;
Coverage of galanthamine salts;
Coverage of oral and parenteral treatment through dependent claims;
Coverage of Alzheimer’s disease and related dementias; and
Early priority relative to the commercial development of galantamine.

Its principal limitations were:

No compound protection;
No composition claims;
No formulation claims;
No manufacturing claims;
No claim to the marketed extended-release technology;
Dose ranges inconsistent with the eventual approved regimen;
Potential factual and legal disputes over “related dementias” and “therapeutically effective amount”; and
Expiration in 2004.

The estate was therefore a pioneering use patent, not a complete product franchise.

Which companies challenged galantamine exclusivity?

Generic manufacturers entered the galantamine market after the primary use patent expired and after relevant product-specific exclusivities and formulation protections became vulnerable or expired. FDA approval records identify multiple generic manufacturers for galantamine tablets, oral solution, and extended-release capsules over time.[3]

The principal competitive groups have included:

Janssen and its commercial successors for Razadyne;
Authorized and independent generic manufacturers;
Contract manufacturers supplying ANDA applicants; and
Companies competing through immediate-release and extended-release dosage forms.

No biosimilar competitor exists because galantamine is a conventional chemical drug. The competitive question has been ANDA approval, formulation equivalence, manufacturing cost, and distribution access.

Were there Paragraph IV challenges or settlement agreements?

Paragraph IV certifications are relevant to later Orange Book-listed patents, particularly formulation and extended-release patents. They are not currently relevant to US 4,663,318 because that patent expired nearly two decades ago.

A generic applicant could have challenged a still-listed later patent by certifying that the patent was invalid, unenforceable, or not infringed. Such a challenge could trigger Hatch-Waxman litigation and a potential 30-month stay. That framework did not preserve the enforceability of US 4,663,318 after its expiration.[4]

There is no current litigation risk based on the six claims supplied by the user. Any historical settlement involving galantamine would need to be tied to a later patent, a specific ANDA, and the relevant product listing. The expired 1987 patent alone cannot support a present settlement restriction.

What patent litigation affects galantamine products?

The current litigation exposure from US 4,663,318 is zero because the patent expired in 2004.

Historical or later disputes could have involved:

Orange Book-listed extended-release patents;
Paragraph IV certifications;
Generic tablet or capsule approvals;
Patent-use-code issues;
Labeling and carve-outs for patented indications;
Manufacturing-process patents; and
Commercial agreements between branded and generic companies.

The supplied claims do not create a current litigation basis against:

A generic galantamine tablet;
A generic oral solution;
A generic extended-release capsule;
A manufacturer of galantamine active pharmaceutical ingredient; or
A distributor selling an FDA-approved generic product.

What generic launch risks exist for galantamine?

Galantamine has low primary-patent risk but may retain execution and product-specific risks.

Risk category	Current assessment
US 4,663,318 infringement	No risk; expired
Compound patent risk	No risk from this patent
Method-of-use risk	No risk from this patent
Orange Book formulation risk	Must be checked against current listings
ANDA approval risk	Product-specific
Bioequivalence risk	Relevant for tablets, solution, and extended-release capsules
Manufacturing risk	Possible if a separate process patent or supplier restriction applies
Regulatory exclusivity	No current exclusivity from US 4,663,318
Biosimilar risk	Not applicable
Commercial pricing risk	High generic competition
Supply-chain risk	Depends on API and finished-dose suppliers

Generic launches may use labeling that omits a patented indication when a later method-of-use patent remains active. That issue is separate from US 4,663,318 and does not apply to an expired patent.

How does US 4,663,318 compare with later galantamine patents?

Patent category	Typical protection	Relationship to US 4,663,318
Early therapeutic-use patent	Galanthamine for Alzheimer’s disease	US 4,663,318
Compound patent	Chemical molecule or salt	Not covered by the supplied claims
Formulation patent	Extended release, dissolution, excipients	Separate later estate
Method-of-use patent	Specific patient group or dosing regimen	Separate later estate
Manufacturing patent	Extraction, synthesis, purification, crystallization	Separate later estate
Regulatory exclusivity	FDA exclusivity period	Separate from patent term
Generic approval	ANDA and bioequivalence	Available after applicable barriers

The commercial patent landscape should therefore be segmented by claim type. Treating the entire galantamine estate as a single patent is legally and commercially inaccurate.

Key Takeaways

US 4,663,318 claimed administering galanthamine or a pharmaceutically acceptable acid-addition salt to treat Alzheimer’s disease and related dementias.
The patent contained method claims, not compound, formulation, or manufacturing claims.
Claims 2 through 7 narrowed the method by route and dose, including oral, parenteral, and intracerebroventricular administration.
The patent issued May 5, 1987, and expired May 5, 2004.
It cannot block current galantamine products, generic launches, or FDA approvals.
Galantamine is a small molecule, so biosimilar analysis does not apply.
Later formulation, extended-release, manufacturing, or product-specific patents must be analyzed separately.
Current commercial risk is driven by FDA requirements, bioequivalence, supply, pricing, and any surviving product-specific rights, not by US 4,663,318.

FAQs

Is US 4,663,318 still enforceable against generic galantamine?

No. The patent expired May 5, 2004, and cannot support an infringement action against a current generic manufacturer.

Did US 4,663,318 patent galantamine hydrobromide?

No. The supplied claims cover administering galanthamine or a pharmaceutically acceptable acid-addition salt. They do not claim the chemical compound or galantamine hydrobromide as a composition.

Does the patent cover Razadyne ER capsules?

Not as a formulation patent. The claims can be read as historical method claims that could encompass administering galanthamine in an oral dosage form, but they do not claim the extended-release capsule structure, release mechanism, or excipient system.

Can a generic manufacturer rely on the patent’s Alzheimer’s disease claims after expiration?

Yes. Once the patent expired, the claimed therapeutic method entered the public domain. A generic manufacturer still must satisfy FDA requirements and must assess any separate unexpired patents.

Are intracerebroventricular galantamine implants commercially protected by this patent?

The patent contains a narrow claim to intracerebroventricular administration through an implanted reservoir. That claim expired in 2004 and no longer provides enforceable protection.

References

U.S. Food and Drug Administration. (2015). Razadyne (galantamine hydrobromide) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products. FDA.
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.
United States Patent and Trademark Office. (1987). U.S. Patent No. 4,663,318: Treatment of Alzheimer’s disease with galanthamine. USPTO.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0236684	⤷ Start Trial	C00236684/01	Switzerland	⤷ Start Trial
European Patent Office	0236684	⤷ Start Trial	SPC/GB00/033	United Kingdom	⤷ Start Trial
European Patent Office	0236684	⤷ Start Trial	2001C/007	Belgium	⤷ Start Trial
European Patent Office	0236684	⤷ Start Trial	C300140	Netherlands	⤷ Start Trial
European Patent Office	0236684	⤷ Start Trial	3/2001	Austria	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,663,318

Summary for Patent: 4,663,318